"Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
| Descriptor ID |
D009369
|
| MeSH Number(s) |
C04
|
| Concept/Terms |
Neoplasms- Neoplasms
- Neoplasia
- Neoplasias
- Neoplasm
- Tumors
- Tumor
Cancer- Cancer
- Cancers
- Malignant Neoplasms
- Malignant Neoplasm
- Neoplasm, Malignant
- Neoplasms, Malignant
- Malignancy
- Malignancies
Benign Neoplasms- Benign Neoplasms
- Neoplasms, Benign
- Benign Neoplasm
- Neoplasm, Benign
|
Below are MeSH descriptors whose meaning is more general than "Neoplasms".
Below are MeSH descriptors whose meaning is more specific than "Neoplasms".
This graph shows the total number of publications written about "Neoplasms" by people in this website by year, and whether "Neoplasms" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 2 | 0 | 2 |
| 1999 | 2 | 0 | 2 |
| 2002 | 1 | 0 | 1 |
| 2003 | 2 | 2 | 4 |
| 2005 | 1 | 0 | 1 |
| 2006 | 2 | 0 | 2 |
| 2007 | 2 | 0 | 2 |
| 2008 | 3 | 1 | 4 |
| 2009 | 1 | 1 | 2 |
| 2010 | 1 | 0 | 1 |
| 2011 | 2 | 0 | 2 |
| 2013 | 2 | 1 | 3 |
| 2014 | 1 | 0 | 1 |
| 2015 | 3 | 2 | 5 |
| 2016 | 1 | 2 | 3 |
| 2017 | 5 | 1 | 6 |
| 2018 | 4 | 2 | 6 |
| 2019 | 1 | 1 | 2 |
| 2020 | 5 | 0 | 5 |
| 2021 | 9 | 0 | 9 |
| 2022 | 4 | 0 | 4 |
| 2023 | 3 | 0 | 3 |
| 2025 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Neoplasms" by people in Profiles.
-
Structured Personalized Oxygen and Supportive Therapies for Dyspnea in Oncology (SPOT-ON): A personalized randomized clinical trial protocol. PLoS One. 2025; 20(12):e0336691.
-
Children's Oncology Group 2023 blueprint for research: Adolescent and young adult oncology. Pediatr Blood Cancer. 2023 09; 70 Suppl 6:e30564.
-
Bispecific antibodies targeting CTLA-4: game-changer troopers in cancer immunotherapy. Front Immunol. 2023; 14:1155778.
-
Variability in COVID-19 Vaccine Response Among People With Cancer: What Health Care Strategy Best Protects the Vulnerable? JAMA Oncol. 2023 02 01; 9(2):177-179.
-
Can Risk Stratification Tools Be Utilized to Safely Discharge Low-Risk Febrile Neutropenic Patients from the Emergency Department? J Emerg Med. 2023 Jan; 64(1):111-118.
-
Creation of a quality improvement collaborative to address adolescent and young adult cancer clinical trial enrollment: ATAQI (AYA trial access quality initiative). Curr Probl Cancer. 2023 Dec; 47(6):100898.
-
Advances in therapeutic targeting of immune checkpoints receptors within the CD96-TIGIT axis: clinical implications and future perspectives. Expert Rev Clin Immunol. 2022 Dec; 18(12):1217-1237.
-
Death Anxiety and Correlates in Cancer Patients Receiving Palliative Care. J Palliat Med. 2023 02; 26(2):235-243.
-
Immune Checkpoint Inhibitor-Associated Myositis: A Distinct Form of Inflammatory Myopathy. J Clin Rheumatol. 2022 Oct 01; 28(7):367-373.
-
Praluzatamab Ravtansine, a CD166-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial. Clin Cancer Res. 2022 05 13; 28(10):2020-2029.